Diabetes

Although investigators found a lack of strong evidence to support CGM programs in community pharmacy settings, studies in ambulatory care settings suggest that these programs are both feasible and beneficial.

Catch up on the latest pharmacy issues and trends with Doug Long, vice president of industry relations at IQVIA.

A study from Bavaria, Germany, found the frequency was higher among boys and children younger than the median age of 6.5 years during the pandemic.

Patients may not experience any early symptoms, making screening especially important.

Patients with diabetes taking a GLP-1 RA of any type had an increased risk of a new GERD diagnosis.

The approval was based on safety and efficacy data from 30 participants in 2 open-label, single-arm studies that received 1 to 3 infusions of donislecel.

Nearly two-thirds of individuals with T2D eventually develop atherosclerotic cardiovascular disease in the United States.

Over 37 million people in the United States have diabetes and are at risk for eye disease, with diabetic retinopathy (DR) being the leading cause of blindness in working-age adults.

Individuals with type 1 diabetes (T1D) had brain atrophy patterns equivalent to a brain age about 6 years older than their actual age.

Doing small spurts of exercise throughout the day provide numerous benefits.

What can CGM's provide for individuals who don't have diabetes?

Insulet plans to commercialize the new product in the United States starting in 2024.

The MiniMed 780G has been available in Europe since 2020.

Tirzepatide was associated with a greater reduction in hemoglobin A1c and body weight when compared to semaglutide. But with a current list price of $1,023 for a one-month supply, is tirzepatide (Mounjaro; Lilly) worth it?

Pharmacists can provide support and guidance to patients during their month of fasting.

According to a recent study, the diabetes medication semaglutide is more effective as a 25 mg or 50 mg dose on its own, rather than a 14 mg add-on dose with other medications.

Speakers at the 2023 virtual Value-Based Insurance Design Summit discussed government programs and company initiatives to advance health equity, as well as the role of research and advocacy to achieve pharmacoequity.

About 1 in 10 individuals in the United States have diabetes. A recent study examines how much they are paying on average for access to treatment for the common disease.

The company also will establish a $35 out-of-pocket price cap for for all patients with commercial insurance that use Latnus

Significant differences in the use of insulin pump and/or CGM technology were noted based on demographic and socioeconomic factors

Leading health organizations are urging those with diabetes and other chronic conditions to get the influenza vaccine.

Not only were people with newly diagnosed type 2 diabetes less likely to develop dementia if they took pioglitazone, but the benefit was stronger among patients with a history of ischemic heart disease or stroke.

Two studies found digital therapeutics can help patients manage their type 2 diabetes effectively regardless of race or ethnicity.

A smartphone app is associated with improvement in HbA1c levels, but physician involvement with patients and other factors may be the benefit.

Pharmaceutical companies are experiencing supply chain disruptions and shortages because of the popularity of diabetes drugs used for weight loss.

Results of a phase 3 clinical trial represent another avenue of treatment for children and adolescents living with type 2 diabetes.

According to the study, vitamin D was beneficial in decreasing the risk for diabetes and increasing the rate of regression back to normal glucose regulation.

Mallya can provide convenience for insulin pen users; however, it has yet to be released in the United States.

The new medication reduces HbA1c and improves glycemic control as an adjunct to diet and exercise.